Among the activated Tregs that infiltrate cancer microenvironments, cells with high chemokine receptor (CCR)4 expression that intensify antitumor immunity via anti‐CCR4 antibodies have been reported in malignant melanoma,3 and individual cancer patients possess specific cancer microenvironments and immune cell profiles. This evidence concerns the gene CCR4 and melanoma.